Pain Management Discoveries and Treatment
- Submitted by: aadolfst01
- Views: 62
- Category: Other
- Date Submitted: 09/02/2016 12:19 AM
- Pages: 3
- Report this Essay
Bharat Book Bureau provides the report, on “Pain Management Discoveries and Treatment Options”. https://www.bharatbook.com/healthcare-market-research-reports-623077/pain-management-discoveries-treatment-options-deterrent-era.html The report to provide improvements over existing formulations for abuse deterrent purpose.
Bharatbook.com announces a report on “Pain Management Discoveries and Treatment Options”. The report discussed a number of novel delivery technologies employed in the formulating abuse deterrent product.
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA
• Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs
• Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain
Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating “Abuse Deterrent Era” in a short span to stop opioid abuse and reversing opioid epidemic in USA. There were around 18,893deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).
Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose. But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to...
Bharatbook.com announces a report on “Pain Management Discoveries and Treatment Options”. The report discussed a number of novel delivery technologies employed in the formulating abuse deterrent product.
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA
• Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs
• Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain
Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating “Abuse Deterrent Era” in a short span to stop opioid abuse and reversing opioid epidemic in USA. There were around 18,893deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).
Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose. But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to...